A sponsor issues an urgent safety communication notifying investigators of a new contraindication discovered during a trial. The investigator's FIRST action should be:
-
A
Await FDA guidance before acting on the sponsor's communication
-
B
Review currently enrolled participants for the contraindication and take protective action immediately
-
C
Notify the IRB and wait for approval before reviewing participant records
-
D
Discuss the communication at the next investigator meeting